MedDataX Logo

Micronutrient-supplemented Milk Study in Women of Childbearing Age

NCT ID: NCT01712165

Last Updated: 2013-10-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if consuming ANMUM Materna (a fortified milk product) over a 12-week period increases red blood cell folate concentrations in women of childbearing age in Singapore, compared to an equivalent amount of standard (unfortified) milk.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Folic acid (\~400 µg/day) taken around the time of conception significantly reduces the risk of a neural tube defect (NTD)-affected pregnancy. Strategies to reduce NTD with folic acid, include supplement use and food fortification. An attractive strategy for NTD prevention is the use of fortified foods targeted for use by women planning a pregnancy. Fonterra currently markets a fortified-milk (ANMUM Materna) in Asia, designed for use prior to and during pregnancy. This milk product, if consumed as directed, provides \~400 µg folic acid per day. It is not known whether ANMUM Materna will reduce NTD rate. However, in a case-control study the risk of NTD was inversely associated with maternal red blood cell (RBC) folate concentrations. Accordingly, if ANMUM Materna increases RBC folate, it could be expected to decrease NTD risk.

In this study, the ANMUM Materna fortified milk will be tested against a standard control (unfortified) milk over a 12 week period. The subjects will consume 75g of milk powder daily throughout the supplementation period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Increase the Concentration of Folic Acid in Women of Childbearing Age

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Folic acid supplement Neural tube defect-affected pregnancy Homocysteine concentration Plasma Folate concentration Plasma vitamin B12 concentration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ANMUM Materna

75g milk powder in 400 ml water daily for 12 weeks.

Group Type ACTIVE_COMPARATOR

ANMUM Materna

Intervention Type DIETARY_SUPPLEMENT

Control

75g of milk powder in 400 ml water for 12 weeks.

Group Type PLACEBO_COMPARATOR

Control (milk powder)

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ANMUM Materna

Intervention Type DIETARY_SUPPLEMENT

Control (milk powder)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female 21-35 years old.
* Able to understand the nature and purpose of the study, including potential risks and side effects.
* Willing to consent to study participation and to comply with study requirements.
* Negative Pregnancy test at screening

Exclusion Criteria

* Consumption of vitamins and/or mineral supplements known to contain folate 6 months prior.
* Chronic disease.
* Milk and/or lactose-intolerant.
* Pregnancy in the last 12 months, or currently planning a pregnancy.
* Prior history of NTD-affected pregnancy
* Serum Folate deficiency
Minimum Eligible Age

21 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Changi General Hospital

OTHER

Sponsor Role collaborator

Fonterra Research Centre

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Magdalin Cheong

Role: PRINCIPAL_INVESTIGATOR

Changi General Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Changi General Hospital

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Singapore

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FON-ALTHEA-SG-2012-01

Identifier Type: -

Identifier Source: org_study_id